(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
3 days till quarter result
(amc 2024-05-08)
Expected move: +/- 6.23%
Live Chart Being Loaded With Signals
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer...
Stats | |
---|---|
今日成交量 | 11.04M |
平均成交量 | 4.52M |
市值 | 300.01M |
EPS | $0 ( 2024-03-11 ) |
下一个收益日期 | ( $-0.0300 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -443.00 |
ATR14 | $0.0240 (0.54%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-26 | Mccarthy Sean A. | Buy | 109 768 | Common Stock |
2024-03-26 | Mccarthy Sean A. | Sell | 109 768 | Stock Option (Right to Buy) |
2024-03-20 | Su Zhen | Buy | 76 000 | Stock Option (Right to Buy) |
2024-03-20 | Su Zhen | Buy | 0 | |
2024-03-19 | Rowland Lloyd A | Sell | 5 268 | Common Stock |
INSIDER POWER |
---|
64.87 |
Last 98 transactions |
Buy: 4 891 928 | Sell: 1 103 909 |
音量 相关性
CytomX Therapeutics Inc 相关性 - 货币/商品
CytomX Therapeutics Inc 财务报表
Annual | 2023 |
营收: | $101.21M |
毛利润: | $99.04M (97.85 %) |
EPS: | $-0.00770 |
FY | 2023 |
营收: | $101.21M |
毛利润: | $99.04M (97.85 %) |
EPS: | $-0.00770 |
FY | 2022 |
营收: | $53.16M |
毛利润: | $47.31M (88.98 %) |
EPS: | $-1.480 |
FY | 2021 |
营收: | $69.57M |
毛利润: | $69.57M (100.00 %) |
EPS: | $-1.300 |
Financial Reports:
No articles found.
CytomX Therapeutics Inc
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。